Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B

Trial Profile

Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
    • 04 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 30 Sep 2018.
    • 05 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top